Found 5 results
Name | Type of Offering | Accepted Date |
---|---|---|
PRESBYOPIA THERAPIES, LLC
|
D | 2016-06-29 18:54:05 |
Amount To Be Raised
$3,400,000
Associated Brokers / Dealers
N/A
CIK Number
0001678518
Filed Document
0001678518-16-000001
Exclusions or Exemptions
506b
Accepted Date
2016-06-29 18:54:05
Type of Offering
D
Industry
Pharmaceuticals
Offering Tier
N/A
Principal Place of Business
CALIFORNIA
Revenue or Assets
No Revenues
Type of Security
Equity
|
||
PRESBYOPIA THERAPIES, INC.
|
D | 2020-11-09 14:20:29 |
Amount To Be Raised
$68,250,000
Associated Brokers / Dealers
N/A
CIK Number
0001678518
Filed Document
0001104659-20-122958
Exclusions or Exemptions
506b
Accepted Date
2020-11-09 14:20:29
Type of Offering
D
Industry
Pharmaceuticals
Offering Tier
N/A
Principal Place of Business
CALIFORNIA
Revenue or Assets
Decline to Disclose
Type of Security
Equity
|
||
Lenz Therapeutics, Inc.
|
D | 2023-03-10 15:01:20 |
Amount To Be Raised
$83,499,961
Associated Brokers / Dealers
N/A
CIK Number
0001678518
Filed Document
0001678518-23-000001
Exclusions or Exemptions
506b
Accepted Date
2023-03-10 15:01:20
Type of Offering
D
Industry
Biotechnology
Offering Tier
N/A
Principal Place of Business
CALIFORNIA
Revenue or Assets
Decline to Disclose
Type of Security
Equity
|
||
PRESBYOPIA THERAPIES, LLC
|
D | 2020-09-14 07:55:43 |
Amount To Be Raised
$250,000
Associated Brokers / Dealers
N/A
CIK Number
0001678518
Filed Document
0001104659-20-104606
Exclusions or Exemptions
506b
Accepted Date
2020-09-14 07:55:43
Type of Offering
D
Industry
Pharmaceuticals
Offering Tier
N/A
Principal Place of Business
CALIFORNIA
Revenue or Assets
Decline to Disclose
Type of Security
Debt
|
||
Lenz Therapeutics, Inc.
|
D/A | 2022-11-22 12:15:48 |
Amount To Be Raised
$49,002,348
Associated Brokers / Dealers
N/A
CIK Number
0001678518
Filed Document
0001678518-22-000002
Exclusions or Exemptions
506b
Accepted Date
2022-11-22 12:15:48
Type of Offering
D/A
Industry
Biotechnology
Offering Tier
N/A
Principal Place of Business
CALIFORNIA
Revenue or Assets
Decline to Disclose
Type of Security
Equity
|